Market
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal
Tempus AI acquired Personalis for $1.5 billion in an all-stock deal focused on precision oncology. Personalis' minimal residual disease (MRD) testing platform will be integrated into Tempus' oncology portfolio, expanding the combined company's diagnostic and data capabilities in cancer care.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network